Pipeline Overview

Category	Product Candidate	Indication	Discovery	Preclinical	Phase 1	Phase 2	Phase 3	Market
Virology: Liver
	HCV	Protease Inhibitor	Glecaprevir (part of pangenotypic, 2-DAA combo)
	HBV	Core Inhibitor	EDP-514
Virology: Respiratory
	RSV	N-Protein Inhibitor	EDP-938 RSVPEDs
			RSV	N-Protein Inhibitor	EDP-938 RSVTx
			RSV	N-Protein Inhibitor	EDP-938 RSVHR
		RSV	L-Protein Inhibitor	EDP-323
	Dual hMPV/RSV	Non-Fusion Inhibitor
	COVID-19	Protease Inhibitor	EDP-235 SPRINT
		RSV	3CL PL Protease Inhibitor
For Out-Licensing
	NASH	FXR Agonists	EDP-305 (Phase 2), EDP-297 (Phase 1)

Virology: Liver
HCV Protease Inhibitor
Discovery	Preclin	Phase 1	Phase 2	Phase 3	Market
Glecaprevir (part of pangenotypic, 2-DAA combo)
HBV Core Inhibitor
Discovery	Preclin	Phase 1	Phase 2	Phase 3	Market
EDP-514

Virology: Respiratory
RSV N-Protein Inhibitor
Discovery	Preclin	Phase 1	Phase 2	Phase 3	Market
EDP-938 RSVPEDs
RSV N-Protein Inhibitor
Discovery	Preclin	Phase 1	Phase 2	Phase 3	Market
EDP-938 RSVTx
RSV N-Protein Inhibitor
Discovery	Preclin	Phase 1	Phase 2	Phase 3	Market
EDP-938 RSVHR
RSV L-Protein Inhibitor
Discovery	Preclin	Phase 1	Phase 2	Phase 3	Market
EDP-323
Dual hMPV/RSV Non-Fusion Inhibitor
Discovery	Preclin	Phase 1	Phase 2	Phase 3	Market
COVID-19 3CL PL Protease Inhibitor
Discovery	Preclin	Phase 1	Phase 2	Phase 3	Market
EDP-235 SPRINT
COVID-19 PL Protease Inhibitor
Discovery	Preclin	Phase 1	Phase 2	Phase 3	Market

For Out-Licensing
NASH FXR Agonists
Discovery	Preclin	Phase 1	Phase 2	Phase 3	Market
EDP-305 (Phase 2), EDP-297 (Phase 1)

*Fixed-dose combination contains glecaprevir and AbbVie's NS5A inhibitor, pibrentasvir. Marketed by AbbVie as MAVYRET (U.S.) and MAVIRET (ex-U.S.).